For the MS patients we demonstrated that the expression of genes involved in IFN-related pathways is strongly induced by IFN-beta therapy in those patients with low endogenous IFN-like activity, but is only weakly induced in patients with high endogenous IFN-like activity. This evidence concerns the gene IFNA1 and myeloid sarcoma.